BEST AVAILABLE COPY

The Patent Office
PATENTS • DESIGNS • COPYRIGHT • TRADE MARKS

INVESTOR IN PEOPLE

The Patent Office
Concept House
Cardiff Road
Newport
South Wales
NP10 8QQ

I, the undersigned, being an officer duly authorised in accordance with Section 74(1) and (4) of the Deregulation & Contracting Out Act 1994, to sign and issue certificates on behalf of the Comptroller-General, hereby certify that annexed hereto is a true copy of the documents as originally filed in connection with the patent application identified therein.

In accordance with the Patents (Companies Re-registration) Rules 1982, if a company named in this certificate and any accompanying documents has re-registered under the Companies Act 1980 with the same name as that with which it was registered immediately before re-registration save for the substitution as, or inclusion as, the last part of the name of the words "public limited company" or their equivalents in Welsh, references to the name of the company in this certificate and any accompanying documents shall be treated as references to the name with which it is so re-registered.

In accordance with the rules, the words "public limited company" may be replaced by p.l.c., plc, P.L.C. or PLC.

Re-registration under the Companies Act does not constitute a new legal entity but merely subjects the company to certain additional company law rules.

CERTIFIED COPY OF
PRIORITY DOCUMENT

Signed P. Mahoney

Dated 7 October 2004

THIS PAGE BLANK (USPTO)
BEST AVAILABLE COPY

THIS PAGE BLANK (USPTO)

Patents Form 1/77

Patents Act 1977
(Rule 16)

The Patent Office

1/77

15MAR99 E432555 1 D00085
P01/7700 0.00 - 9905807.5

Request for grant of a patent

(See the notes on the back of this form. You can also get an explanatory leaflet from the Patent Office to help you fill in this form)

12 MAR 1999

The Patent Office

Cardiff Road
Newport
Gwent NP9 1RH

1. Your reference — PP/2326

2. Patent application number *(The Patent Office will fill in this part)* — **9905807.5** — 12 MAR 1999

3. Full name, address and postcode of the or of each applicant *(underline all surnames)*

AMERSHAM PHARMACIA BIOTECH UK LIMITED
Amersham Place
Little Chalfont
Buckinghamshire
HP7 9NA

Patents ADP number *(if you know it)* 75529120001

If the applicant is a corporate body, give the country/state of its incorporation — UNITED KINGDOM

- SEE CONTINUATION SHEET

4. Title of the invention — ANALYSIS OF DIFFERENTIAL GENE EXPRESSION

5. Name of your agent *(if you have one)*

"Address for service" in the United Kingdom to which all correspondence should be sent *(including the postcode)*

STEVENS HEWLETT & PERKINS
1 Serjeants' Inn
Fleet Street
LONDON
EC4Y 1NT

form 51/77 22-3.00

A J Bollans
Nycomed Amersham plc
Amersham Laboratories
White Lion Road
Amersham
Bucks
HP7 9LL

1545003

Patents ADP number *(if you know it)*

6. If you are declaring priority from one or more earlier patent applications, give the country and the date of filing of the or of each of these earlier applications and *(if you know it)* the or each application number

Country	Priority application number *(if you know it)*	Date of filing *(day / month / year)*

7. If this application is divided or otherwise derived from an earlier UK application, give the number and the filing date of the earlier application

Number of earlier application	Date of filing *(day / month / year)*

8. Is a statement of inventorship and of right to grant of a patent required in support of this request? *(Answer 'Yes' if:*

a) any applicant named in part 3 is not an inventor, or
b) there is an inventor who is not named as an applicant, or
c) any named applicant is a corporate body.
See note (d))

Yes

Patents Form 1/77

9. Enter the number of sheets for any of the following items you are filing with this form. Do not count copies of the same document

Continuation sheets of this form	1
Description	11
Claim(s)	2
Abstract	
Drawing(s)	3 +3

10. If you are also filing any of the following, state how many against each item.

Priority documents	
Translations of priority documents	
Statement of inventorship and right to grant of a patent *(Patents Form 7/77)*	
Request for preliminary examination and search *(Patents Form 9/77)*	1
Request for substantive examination *(Patents Form 10/77)*	
Any other documents *(please specify)*	

11. I/We request the grant of a patent on the basis of this application.

Signature [signature] Date 12-03-99

Agents for the Applicant

12. Name and daytime telephone number of person to contact in the United Kingdom: P Pennant; 0171-936-2499

Warning

After an application for a patent has been filed, the Comptroller of the Patent Office will consider whether publication or communication of the invention should be prohibited or restricted under Section 22 of the Patents Act 1977. You will be informed if it is necessary to prohibit or restrict your invention in this way. Furthermore, if you live in the United Kingdom, Section 23 of the Patents Act 1977 stops you from applying for a patent abroad without first getting written permission from the Patent Office unless an application has been filed at least 6 weeks beforehand in the United Kingdom for a patent for the same invention and either no direction prohibiting publication or communication has been given, or any such direction has been revoked.

Notes

a) If you need help to fill in this form or you have any questions, please contact the Patent Office on 0645 500505.

b) Write your answers in capital letters using black ink or you may type them.

c) If there is not enough space for all the relevant details on any part of this form, please continue on a separate sheet of paper and write "see continuation sheet" in the relevant part(s). Any continuation sheet should be attached to this form.

d) If you have answered 'Yes' Patents Form 7/77 will need to be filed.

e) Once you have filled in the form you must remember to sign and date it.

f) For details of the fee and ways to pay please contact the Patent Office.

3. **NAME, ADDRESS POSTCODE OF SECOND APPLICANT**

AMERSHAM PHARMACIA BIOTECH INC
800 Centennial Avenue
P O Box 1327
Piscataway
New Jersey
08855-1327
USA

739527000 1

COUNTRY/STATE OF INCORPORATION

NEW JERSEY

DUPLICATE

ANALYSIS OF DIFFERENTIAL GENE EXPRESSION

This invention relates to methods for detecting the differential expression or presence of two analytes, and more specifically to procedures which provide for rapid and efficient analysis of gene expression in biological systems.

Analysis of cellular gene expression is key to gaining understanding of the function of biological organisms and to elucidating the mechanisms which control key cellular events, knowledge of which is crucial to the development of drugs and strategies for treatment of disease states arising from disruption of cellular control processes.

A wide variety of methods have been developed for analysing gene expression, both at the level of MRNA expression, or by examining the amounts of specific proteins present in cells. Most methods have the same experimental basis in that they examine differential expression; that is they examine the difference in expression of one or more cellular components between two cells which have been exposed to different conditions. Such studies typically compare expression levels in cells of an untreated population (the control cells) with expression in a separate population of the same cell type (the test cells) that have been subjected to some form of stimulus, for example exposure to a hormone, drug or other chemical.

Early methods for the analysis of differential gene expression were predominantly based on analysis of (often anonymous) MRNA bands on electrophoresis gels. Such approaches have largely been displaced by more powerful, reproducible and informative methods based on the use of arrays of nucleic acids in which large numbers of specific sequences are laid down in an ordered pattern on a solid surface and form the target for hybridisation and capture of labelled MRNA or CDNA from the cells under

study. Such arrays have been constructed on a variety of supports, ranging from nylon membranes to glass and silicon wafers. Whatever the support, the essential method of use is the same; firstly known sequences, complementary to cellular mRNAs, either in the form of synthetic oligonucleotides or as PCR products, are laid down on the solid support in spots at defined locations. These immobilised sequences (targets) are then exposed to sequences (probes) extracted from the cells or tissue under study, where the probes are tagged with some form of label which can be detected in subsequent analysis.

In early techniques, radioactive labels were used to probe targets on nylon membranes using techniques developed from Southern and Northern blotting methods. However these methods required the hybridisation process to be performed twice, once for the control sample and once for the test sample. They were subsequently overtaken by more elegant procedures based on the use of different coloured fluorophors to label control and test probes and using either PCR products coupled to glass (Schena M. *et al*, (1996), Proc. Natl. Acad. Sci., 93 (20), 10614-10619) or oligonucleotides synthesised directly onto glass using photo-lithographic techniques (Chee M. *et al*, (1996), Science 274 (5287), 610-61) to form what are commonly termed 'micro-arrays'.

In both methods the MRNA sequences extracted from control and test cells or tissues are either labelled directly or are first converted or amplified to yield equivalent CDNA sequences which are subsequently labelled. Once immobilised by hybridisation to complementary target sequences located on the array, the fluorescent labels attached to the probes are detected, either by scanning or by imaging, and quantified to yield data on the amounts of different mRNAs present in the test and control samples. Since sequences from test and control cells are labelled with different fluorophors, both samples can be applied and hybridised simultaneously and the resulting pattern and intensity of hybridised probes determined using detection instrumentation tuned to distinguish between

the emission wavelengths of the fluorophors used.

Consequently these two-colour methods allow direct visualisation of differential expression of mRNAs between the two cell populations and are widely used in many fields of life science research to study the control and consequences of gene expression.

However, despite the relative simplicity and elegance of these methods, in operation they suffer from a number of technical difficulties which limit the ease of application and the speed of the techniques to the analysis of gene expression. The construction of target arrays is a time consuming and often expensive process requiring precision equipment; either for construction and alignment of the masks required for light directed oligonucleotide synthesis, or for precise application of nanolitre droplets of liquid for DNA arrays. Arrays based on DNA spots also suffer from artefacts arising from unequal application or drying of the very small volumes used, and often require replicate spots to yield accurate data. With either type of array, if the user wishes to modify his investigations to include additional sequences a whole array must be constructed to accommodate the new targets. It would not be atypical to have to make an entirely new array simply to add a single new sequence to a pre-existing library of several thousand sequences.

The hybridisation process is also subject to a number of problems arising from the geometry of the system and the temperature required for the hybridisation process. To achieve sufficient sensitivity to detect low levels of mRNAs it is necessary to use a high concentration of labelled probe to achieve maximal hybridisation to target sequences; this requirement and the limited amount of probe material available results in hybridisation reactions being performed in very small volumes. Difficulties therefore arise in ensuring adequate coverage of arrays with microlitre quantities of solution, and the resulting thin films of liquid do not promote good access of the mobile probe sequences to the fixed target sequences; furthermore problems with evaporation are also common at the

temperatures of 400°C to 650°C commonly used for hybridisation.

Finally, the detection and quantification of fluorophor-labelled probes on micro-arrays requires dedicated sophisticated equipment to detect the very low levels of fluorescence present. To achieve the required sensitivity, detection is most commonly achieved using a scanning laser spot to excite fluorophor molecules; this can be a very slow process requiring up to several hours to complete measurements from a single array.

This invention provides an alternative to micro-array systems for analysis of gene expression. Means are provided for performing analyses using a particle based technique so as to replace ordered 2D arrays with randomly oriented 3D arrays which can be quickly and easily modified to include new target sequences. The technique provides favourable geometry and kinetics for promoting efficient hybridisation, that can be performed in a standard reaction tube, and that allows measurement of hybridised probe to several thousand target sequences to be accomplished in a few seconds.

The invention provides a method of detecting and analysing differences between nucleic acids from two sources, which method comprises:

a. providing nucleic acids from two sources as labelled probes;

b. forming a mixture of the labelled probes with pooled reagents wherein each reagent is a population of beads carrying a polynucleotide target, the target of one reagent being different from the target of another reagent, the beads of one reagent being distinguishable from the beads of another reagent;

c. incubating the mixture under conditions to promote specific hybridisation between probes and targets; and,

d. analysing beads in the mixture by flow cytometry.

A polynucleotide target is partly or wholly single-stranded and is capable of specific hybridisation. Oligonucleotides of at least 8 residues

are possible. Preferred are cDNA sequences derived, e.g. by PCR amplification, from cellular mRNA.

The pooled reagents may comprise one bead, or preferably a plurality of beads, of each reagent.

Features of the invention include:

a) gene expression assays are performed on carrier beads;

b) individually identifiable beads or populations of beads each carrying a different target sequence are prepared;

c) selected beads, or populations of beads, are pooled together in suspension to provide a randomly oriented 3D array of particles carrying all sequences of interest for an individual investigation;

d) mRNAs or cDNAs prepared from control and test cells or tissues are labelled with fluorescent tags to identify their source;

e) labelled probe species are mixed with the pooled suspension of target carrying beads under conditions which promote specific hybridisation between probes and targets;

f) the bead mixture is analysed by flow cytometry to simultaneously determine the identity of each bead analysed (and hence the identity of the target sequence carried by the bead) and to quantify the amounts of both control and test probes bound to each bead; and

g) data is analysed to yield information on the relative and absolute abundance of each MRNA in the control and test samples.

For clarity one embodiment of the invention is described with reference to the following figures:

Figure 1: Schematic illustration of 2D ordered array and 3D random array.

Figure 2: Flowchart illustrating the principle of the bead based flow cytometry gene expression process.

Figure 3: Schematic representation of the bead based flow cytometry gene expression process.

With reference to Figure 1, in a two dimensional ordered

array the locations of each target spot immobilised on a planar surface are defined by x,y co-ordinates and hence target sequences are identified by the same co-ordinates. In contrast, in a 3D array formed from particles dispersed in a space defined by dimensions x,y,z, if each particle is individually identifiable by some inherent characteristic, it is not necessary to use x,y,z locations to specify the identity of each bead and the particles can be randomly distributed throughout the volume as in a suspension of beads in liquid. It follows that if each bead is individually identifiable, then any target sequence previously coupled to that bead is also identifiable. Therefore if a number of differing beads, or discrete populations of beads, are individually prepared where each bead carries a different target sequence and then selectively pooled, the pooled beads can form a 3D array which can be used for gene expression analysis.

Beads suitable for use in the method of the invention are those which can be readily identified during analysis by flow cytometry; such beads have been previously developed and used for diagnostic assays to measure a wide range of analytes in blood and other biological fluids by immunoassay. A desire to have a higher throughput in these applications has led to the development of multiplex methods which allow more than one analyte to be measured simultaneously by means of flow cytometry analysis. Multiplexing is achieved by carrying out solid phase linked assays using plastic or latex beads as assay substrates. By using a number of discrete bead types which are individually distinguishable from each other, where each bead type carries reagents for one assay, standard flow cytometer instrumentation may be used both to identify the bead type and to measure the assay signal associated with each bead. Discrimination between bead populations can be achieved by size (Frengen J. *et al* (1995), Journal of Immunological Methods, Volume 178, p141), by colour or fluorescence (Fulwyier M.J. UK Patent 1,561,042) or by electronic means (Mandecki W. US Patent 5,641,634).

The general principle of the process of the invention is now

described with reference to Figure 2. Selected target CDNA sequences are prepared by standard PCR methods incorporating a means to allow coupling of target sequences to beads. One suitable method would utilise a 5"-biotin on one of the PCR primers, yielding a 5-biotinylated DNA suitable for coupling to a streptavidin-coated beads. Those skilled in the art will recognised that alternative chemical coupling strategies are available and also that oligonucleotides synthesised with a terminal biotin or other coupling group could readily be used in place of PCR generated DNA sequences.

Once the required number of target cDNAs (CDNA 1 to CDNA n) have been prepared, each target sequence is separately coupled to a corresponding discrete population of beads (Bead 1 to Bead n respectively). Aliquots are then removed from each population and pooled to form a mixed suspension of beads constituting a randomly orientated 3D array of target sequences. The 3D array is then hybridised with fluorescently labelled probes (RNA or CDNA) prepared from the control and target cells or tissues which have been labelled with two different fluorophors (Fluor A and Fluor B respectively). Following hybridisation the mixed population of beads is analysed by flow cytometry; as each bead is analysed information from the flow cytometer detectors is used to identify the bead and to measure the amounts of Fluor A (control MRNA) and Fluor B (sample MRNA) bound to the complementary target sequence carried by the bead. These measurements are then used to determine the relative expression of each MRNA in the samples.

In a further illustration of the method of the invention reference is made to one embodiment as shown in Figure 3. Control (1) and test (2) probes are prepared and labelled using standard methods and aliquots mixed in a tube (3) containing a mixture of beads (4) carrying the desired target sequences and the tube sealed. Hybridisation of probe and target sequences are promoted by incubating the mixture under conditions of heat, pH and salt concentration which are known to allow the formation

of specific nucleic acid hybrids. Following hybridisation, the bead mixture is analysed by flow cytometry using multiple channel fluorescence detection. In the embodiment illustrated, two fluorescence channels are used to identify beads and two further channels are used to measure control and test probe fluorescence. For each bead passing through the flow cytometer this data produces a set of data values that can be represented as 3D plots for control probes (7) and test probes (6). Bead identity is determined by measuring the amounts of two different fluorophors (bead Fluor 1 and bead Fluor 2) incorporated within the bead during manufacture. Plotting the intensities of the two fluorophors on x,y axes (8 & 9) separates the different bead populations used.

The number of possible target sequences that can be measured in a single assay will necessarily be limited by the number of bead populations which it is possible to discriminate in a mixture. With current flow cytometry instrumentation this does not pose a limitation on the utility of the procedure. Typical modern flow cytometry instruments are capable of simultaneously measuring fluorescence at four wavelengths together with other parameters, for example light scattering which is a measure of the size of particles under analysis. In addition, the dynamic range of fluorescence detection is high and fluorescence may be accurately measured over several orders of magnitude. Given this sophistication in measurement it is relatively straightforward to devise schemes which yield a large number of individually distinguishable bead populations to serve as carriers. For example if beads are prepared which contain 2 separate fluorophors, with each fluorophor present in one of 10 levels, then $10^2 = 100$ bead types are created. By increasing the number of fluorophors, or the levels of each fluor or by introducing other variables, such as bead size, larger numbers of discrete bead types can be produced.

Plotting the intensity of probe fluorophors on the z axis of two different plots (10 & 11) shows the amounts of the control (10) and test (11) probes bound to each bead population. This allows the production of a

table of the amounts bound to each target sequence in the analysis (14). In the schematic example shown, one MRNA species (12) is expressed at a lower level in the test sample than in the control (13). Other differences in expression can be readily identified as differences in the heights of equivalent peaks in the two plots.

In micro-array technique applications DNA or oligonucleotide target sequences are typically applied to a solid surface as discrete areas of dimensions in the range 10-100 μm, with dimensions of 50-100 μm being typical of DNA spots applied as liquid droplets, and smaller areas being used in techniques utilising photo-lithographic oligonucleotide synthesis. To ensure accuracy in measurement of differential expression it is important that the amount of DNA or oligonucleotide present on the solid phase is in excess of complementary sequences in the probe solution such that target sequences do not become limiting leading to distortion of hybridisation results. Consequently it is crucial that in any procedure using flow cytometry for analysis of gene expression using target sequences carried on beads, that the capacity of the system retains the same degree of target:probe excess as used in conventional techniques. Beads used for flow cytometry typically have diameters in the range from 1-10 μm and therefore individually do not have sufficient surface area to substitute for a typical micro-array. However by using several beads to carry each target sequence it is possible to achieve equivalence in target presentation as shown in the following example:

For a 2D array with 1 00 μm ∅ spots:

spot area $= \pi r^2$

$= 3.14 \times (50)^2$

$= 7850\ \mu m^2$

For 10 μm ∅ beads in beam (50% surface illuminated):

lit area $= 2\pi r^2$

$= 2 \times 3.14 \times (5)^2$

$= 157\ \mu m^2$

Bead:Spot equivalence = 7850 / 157
= 50 beads

Bead volume (assuming cubic packing) $= 10^3\ \mu m^3$
Volume of 50 beads $= 50{,}000\ \mu m^3$
Assuming 10% v/v suspension $= 500{,}000\ \mu m^3$
$= 5 \times 10^5 / 1 \times 10^9\ \mu l$
$= 1 \times 10^{-3}\ \mu l$
$= 1$ nl

Consequently for a complete assay of 1000 targets using 50 beads/target the total volume required for the assay is 1 µl. If desired, larger volumes may be used for convenience in hybridisation or analysis; for example using beads at a concentration of 1 % v/v would give a 10 µl total volume.

If desirable, the method of the invention would allow larger numbers of beads to be used with a consequent increase in capacity for binding a greater mass of target sequence spread over the total bead population. This would allow the user if desired to increase the amount of probe bound to the bead populations to increase the sensitivity of the process for detecting rare species. Alternatively, it enables an increase in the number of samples which may be analysed simultaneously, for example, to measure expression of a panel of genes simultaneously in a control and more than one test sample, where as described previously each control or test sample is labelled with a different fluorophor. Such increases in assay complexity are not achievable with conventional arrays on solid surfaces without reducing sensitivity due to the finite capacity of array spots for binding complementary sequences.

It can be appreciated by the skilled worker that the method of

the present invention provides a number of significant advantages over previously described procedures for gene expression analysis which are based on 2D arrays:

a) the basic components for the bead based assay are readily prepared by coupling solutions of CDNA or oligonucleotides to commercially available beads using standard coupling methods,

b) no specialised equipment is required for preparation or analysis, in contrast to the dedicated array production and scanning equipment required for micro-arrays,

c) the design of investigations can be easily modified with target sequences being added or deleted at will without the requirement to scrap existing materials,

d) hybridisation is performed in suspension in standard reaction vessels, thereby avoiding problems with evaporation associated with thin films of liquid covering micro-arrays and promoting hybridisation through efficient mixing of probe and target sequences, and

e) analysis speed is significantly improved: flow cytometers typically analyse beads at rates of 1,000-10,000 beads/second allowing processing of a 100 sequence gene expression analysis in a few seconds.

CLAIMS

1. A method of detecting and analysing differences between nucleic acids from two sources, which method comprises:

a. providing nucleic acids from two sources as labelled probes;

b. forming a mixture of the labelled probes with pooled reagents wherein each reagent is a population of beads carrying a polynucleotide target, the target of one reagent being different from the target of another reagent, the beads of one reagent being distinguishable from the beads of another reagent;

c. incubating the mixture under conditions to promote specific hybridisation between probes and targets; and,

d. analysing beads in the mixture by flow cytometry.

2. The method of claim 1 wherein the nucleic acids from two sources are mRNA or cDNA from cells or tissues.

3. The method of claim 1 or claim 2 wherein the polynucleotide targets are cDNA derived from cellular mRNA.

4. The method of any one of claims 1 to 3 wherein the polynucleotide targets are PCR amplimers.

5. The method of any one of claims 1 to 4 wherein the polynucleotide targets carry terminal biotin groups through which they are attached to streptavidin-coated beads.

6. The method of any one of claims 1 to 5 wherein beads of one reagent are distinguishable from beads of another reagent by size and/or by the nature and/or the concentration of markers attached to the beads.

7. The method of claim 6 wherein fluorescent markers are attached to the beads.

8. The method of claim 1 or claim 2 wherein each probe is labelled with a fluorescent tag to indicate its source.

9. The method of any one of claims 1 to 8 wherein analysis by flow cytometry is performed to identify each bead and to quantify the probes bound thereto.

10. The method of any one of claims 1 to 9 wherein data obtained by flow cytometry is analysed to yield information about the relative and/or absolute abundances of individual sequences of the nucleic acids from the two sources.

Figure 1



THIS PAGE BLANK (USPTO)

THIS PAGE BLANK (USPTO)

Figure 2


cDNA 1
PCR Reaction 1
Bead 1
cDNA 2
PCR Reaction 2
Bead 2
cDNA 3
PCR Reaction 3
Bead 3
cDNA n
PCR Reaction n
Bead n
POOLED BEADS
FLOW CYTOMETRY
A:B for Bead 1
A:B for Bead 2
A:B for Bead 3
A:B for Bead n
d[mRNA 1]
d[mRNA 2]
d[mRNA 3]
d[mRNA n]
Control Sample (fluor A)
Test Sample (fluor B)

THIS PAGE BLANK (USPTO)

Figure 3


4
3
1
2
Flow Cytometry analysis
10
fluor A
bead fluor 2
9
7
8
bead fluor 1
13
11
fluor B
bead fluor 2
6
9
8
bead fluor 1
12
Bead
Fluor A
Fluor B
Ratio A:B
Differential Expression
14

THIS PAGE BLANK (USPTO)